In a clinical study, 56% of people (74 out of 132) treated with COLUMVI achieved complete or partial remission. Half of those people continued to be in remission at 18.4 months.
Learn how COLUMVI works to treat DLBCL
Access information and tools designed to help you get started
Antibody
A special protein made by the immune system (B cells) to help protect from harmful invaders like viruses or bacteria.
B cell
A type of white blood cell in your immune system that helps protect your body from infection and disease.
Bispecific antibody
Bispecific antibodies are designed to target 2 different cells to bring them closer together, such as an immune cell and cancer cell.
Complete remission
Also called “complete response,” it is the disappearance of all signs of cancer in response to treatment. This does not mean the cancer has been cured.
Continuous treatment
Designed for use until disease worsens or unacceptable side effects occur.
Cycle
The time between one round of treatment until the start of the next.
Cytokine release syndrome (CRS)
A serious side effect that happens when your immune system responds too strongly by rapidly releasing a large amount of substances known as cytokines. CRS may cause fever, fast or irregular heartbeat, low blood pressure, chills, or difficulty breathing.
Diffuse large B-cell lymphoma (DLBCL)
A type of aggressive blood cancer that affects B cells. It is the most common form of non-Hodgkin lymphoma.
Fixed-duration therapy
A treatment that is designed to be administered for a prespecified number of cycles and with a targeted completion.
Large B-cell lymphoma (LBCL)
The most common type of B-cell non-Hodgkin lymphoma (NHL). With NHL, abnormal lymphocytes build up in the lymph nodes, bone marrow, and spleen, DLBCL is a subtype of LBCL.
Overall response
A partial or complete remission.
Partial remission
Also called partial response—some measurable decrease in size of the cancer.
Phase 1/2 clinical trial
The first 2 phases of a clinical trial program that studies an investigational treatment.
Refractory
A term used to describe disease that has not responded to treatment.
Relapsed
A term used to describe disease that has returned after responding to previous treatment.
Remission
The reduction in (partial) or disappearance of (complete) signs and symptoms of cancer in response to treatment.
Step-up dose
A smaller dose of COLUMVI that you receive on Day 8 and Day 15 of your first cycle of treatment.
T cell
A type of white blood cell. T cells are part of the immune system and protect the body from infection. They can also help recognize and destroy abnormal cells like cancer cells.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.